Brief: Seikagaku initiates a phase III clinical trial (additional study) in the U.S. for SI-6603

Seikagaku

19/02/2018 01:34

Feb 19 (Reuters) - Seikagaku Corp  4548.T   
     
    * Says it will initiate a Phase III clinical trial 
(additional 
study) in the U.S. for SI-6603, indicated for the treatment of 
radicular leg pain (i.e. sciatica) due to a lumbar disc 
herniation.  
 
     
    Source text in Japanese:https://goo.gl/1yFkhk 
    Further company coverage: 4548.T  
 
 (Beijing Headline News) 
 ((Beijing.HeadlineNews@thomsonreuters.com; +8601082555111; 
Reuters Messaging: Pingping.Li1@thomsonreuters.com@reuters.net))